Policosanol
Best-in-class: Policosanol
A useful case study in why replication matters. Early Cuban trials reported statin-like lipid effects; independent trials elsewhere found essentially nothing.
Policosanol quick facts
| Suggested dose | Not recommended on current evidence. |
| How often | Not recommended on current evidence |
| Who it's for | Nobody, on the independent data. |
A genuinely instructive cautionary tale. Cuban trials reported LDL reductions rivalling statins; no independent group outside Cuba has ever replicated them, and well-conducted German and other trials found essentially no effect. The most likely explanation is publication and source bias rather than a difference in material. Worth knowing about mainly as an example of why single-source evidence deserves scepticism regardless of how good the numbers look.
How Policosanol actually works
A mixture of long-chain aliphatic alcohols from sugar cane wax, principally octacosanol. The proposed mechanism is modulation of HMG-CoA reductase activity — downregulating the enzyme rather than competitively inhibiting it as statins do — plus effects on LDL catabolism.
Where to get Policosanol
Find Policosanol on iHerb →The evidence for Policosanol
Graded by what exists behind each claim.
✅ Clinically validated
- Numerous positive trials, almost all from a single research group in Cuba.
- Independent randomized trials conducted in Germany, the United States and elsewhere found no significant lipid effect.
📊 Correlative data
- The striking early results came almost entirely from Cuban research groups using Cuban sugarcane-derived material. Independent replication outside Cuba consistently failed, which is one of the clearest examples in the supplement literature of results not surviving a change of investigator.
🧪 Theoretical / extrapolated benefits
- The proposed mechanism was inhibition of cholesterol synthesis; the independent replication failures undercut it.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Policosanol actually does
Policosanol is a wax. Chemically it is a mixture of long-chain primary aliphatic alcohols, from about C24 to C34, with 1-octacosanol (C28, a twenty-eight-carbon straight chain ending in a single hydroxyl) as the dominant component. It is isolated from sugar-cane wax by saponification and purification. There is no heteroatom, no ring, no charge and no obvious binding surface: this is a molecule with essentially nothing on it for a protein to recognize, which is the first thing that should be said about a compound sold as a receptor-level lipid drug.
The proposed mechanism is not statin-like, and the distinction is worth getting right. A statin is a competitive active-site inhibitor of HMG-CoA reductase, because it carries the structural mimic of HMG-CoA. Policosanol carries nothing of the kind. The mechanism proposed for it is indirect regulation — modulation of HMG-CoA reductase activity through the AMP-activated protein kinase phosphorylation switch rather than by occupying the site, together with increased LDL-receptor-dependent catabolism of circulating LDL Gouni-Berthold 2002. Both are real biology in other contexts. Neither has been demonstrated in human tissue with this compound.
The unasked pharmacokinetic question. A C28 primary alcohol is a solid at body temperature and is effectively insoluble in water. The expected metabolic fate of a very-long-chain fatty alcohol is oxidation to the corresponding fatty acid by fatty alcohol dehydrogenase and fatty aldehyde dehydrogenase, followed by chain shortening. Whether any octacosanol reaches the hepatocyte as octacosanol, and at what concentration, has never been established in a published human concentration-time curve. So the mechanism above is a hypothesis about a molecule whose arrival at the proposed site of action is unmeasured.
Which makes this page different from every other one in the cohort. Elsewhere the argument is that a mechanism is real and the exposure is too small. Here the mechanism was never independently demonstrated and the exposure was never measured, and yet a decade of trials reported an effect size that would make a 10 mg tablet competitive with lovastatin Crespo 1999. The interesting question on this page is not biochemical. It is why those two facts coexisted for so long.
Cell, rodent, human — and where it stops
The chain, as it was originally presented. Cell and rodent work reporting effects on cholesterol biosynthesis and LDL catabolism, then a long program of human trials, collected in the review that defined the field before any outside group had tested it Gouni-Berthold 2002.
In people, in Havana, repeatedly, for a decade. A two-year study in type II hyperlipoproteinemia Canetti 1995. A head-to-head against lovastatin in patients with hypercholesterolemia and non-insulin-dependent diabetes Crespo 1999. A six-month double-blind comparison of 20 against 40 mg per day in type II hypercholesterolemia Castano 2001. These are not abstracts or pilot studies; they are multi-year, double-blind, placebo-controlled and dose-ranging, and their reported lipid effects were large. Running an active comparison against a statin Crespo 1999 is a statement about the size of the claim.
Then independent groups looked, and there was nothing there. A German randomized controlled trial allocated 143 patients with hypercholesterolemia or combined hyperlipidemia across five groups — placebo and policosanol at 10, 20, 40 and 80 mg per day. In none of the five treatment groups did LDL-C fall more than 10% from baseline, and no statistically significant difference between policosanol and placebo was observed at any dose Berthold 2006. A Canadian group tested Cuban sugar-cane policosanols in hypercholesterolemic persons and found no cholesterol-lowering efficacy Kassis 2006. A third group ran policosanol against atorvastatin with a placebo arm — the design that can tell a failed drug from a failed trial, because the statin arm is an internal positive control Cubeddu 2006.
The specific obstacle is that there is no obstacle, and that is the finding. Work through the usual explanations for a failed replication and each one is closed off. Dose is not it: the German trial spanned 10 to 80 mg, bracketing everything Havana used Berthold 2006Castano 2001. Duration is not it: the Cuban program ran from six months to two years and the replications ran the standard twelve weeks, which is ample for an LDL pool that re-equilibrates in about three weeks Canetti 1995. Population is not it: both sides enrolled type II hypercholesterolemia. And source material is not it either, which is the point that closes the argument — the Canadian group specifically used Cuban sugar-cane policosanol and still found nothing Kassis 2006.
What is left is the investigator. When dose, duration, population and raw material are all controlled and the result still only appears in one place, the variable that remains is who ran the trial and analyzed it. That is not an accusation of fraud and this page does not make one. It is the statistical meaning of the pattern: an effect that never leaves one research program is a property of the program until proven otherwise. Reporting that plainly is what the evidence supports.
Policosanol — which form, and does it matter
Sugar cane is not the only source, and the alcohol profiles differ. Policosanol is also made from beeswax, rice bran and wheat germ, and the ratio of C24 to C34 alcohols — in particular how much of it is octacosanol — is set by the source. The trials that reported effects used sugar-cane material of a defined profile Gouni-Berthold 2002Castano 2001. A beeswax policosanol is a chemically different mixture that has never been trialed at all.
The source defense has already been tested and it failed. The usual reply when a botanical fails to replicate is that the replicating group used the wrong material. That reply is not available here: an independent group obtained Cuban sugar-cane policosanols and reported no cholesterol-lowering efficacy Kassis 2006. This is unusual and it is worth stating clearly — the wrong-material explanation is normally impossible to rule out, and in this one case somebody ruled it out.
What a label tells you. Most bottles declare total policosanol in milligrams and, if you are lucky, an octacosanol percentage. Neither number maps onto anything, because there is no dose at which an independent trial has seen an effect Berthold 2006. A standardization argument only helps when the standardized article works.
And a warning about what else is in the bottle. Policosanol is frequently sold inside cholesterol blends alongside red yeast rice, plant sterols, berberine or bergamot. In that context the milligrams of policosanol are decoration and the lipid effect, if there is one, belongs to whichever ingredient has independent evidence. Read the panel, and attribute the result to the ingredient the literature supports.
What would have to be true, and how you would know it was not
1. LDL Cholesterol (calculated), mg/dL — unchanged. This is the whole prediction and it is unusually confident, because the replication covered a fourfold dose range and none of the five arms moved LDL-C by more than 10% from baseline Berthold 2006. Draw before the first capsule and again at 12 weeks, fasting, same laboratory. Predict the two numbers differ by less than the assay's own reproducibility.
2. Apolipoprotein B, mg/dL — unchanged. ApoB counts atherogenic particles rather than the cholesterol inside them, so it is the harder number to move by accident and the better test of a lipid claim. Predict less than 5% change at 12 weeks.
3. The prediction that cuts against this page rather than against the product. If your LDL-C falls 20% on 20 mg of policosanol, that is a genuinely surprising result and this page is wrong about you. So run it properly: two baseline draws two weeks apart before you start, because within-person LDL-C variability is around 8–10% and a single pair of draws will manufacture a 12% improvement out of nothing. If the effect survives two baselines and a rechallenge, it is worth reporting to somebody, because no independent group has produced it Berthold 2006Kassis 2006.
4. Stopping it should change nothing, and that is a free experiment. Discontinue for 12 weeks and redraw. A real lipid-lowering agent produces a measurable rebound as the LDL pool re-equilibrates over about three weeks; this predicts a flat line. A washout is the cheapest single-person test on this page and almost nobody runs one.
What will fool you: the season. Lipids run higher in winter and lower in summer in most populations, by an amount comparable to the effect being claimed. A supplement started in January and re-measured in June has a tailwind.
What nobody has tested yet
Nobody has published a human plasma concentration-time curve for octacosanol. This is the single missing measurement that would reframe the whole argument. Give twelve fasted volunteers 20 mg, draw at 0, 2, 4, 6, 8, 12 and 24 hours, and quantify octacosanol and its oxidation products by gas chromatography-mass spectrometry. If plasma octacosanol is undetectable, the Cuban results need an explanation that is not pharmacological. If it is detectable at concentrations that could plausibly touch an intracellular kinase, then the replication failure becomes genuinely puzzling rather than predictable.
Nobody has run an independently monitored trial in Cuba. That is the experiment that separates the two candidate explanations — population or process. Same investigators, same material, same patients, with randomization, blinding, data capture and statistical analysis contracted to an outside group. It has been the obvious study since 2006 and nobody has funded it Berthold 2006Cubeddu 2006.
Nobody has released the individual patient data. The Havana program covers years of double-blind trials Canetti 1995Crespo 1999Castano 2001. Individual patient data would allow the usual forensic checks — baseline balance, digit preference, variance patterns — that resolve questions of this kind without anyone having to accuse anyone of anything.
And nobody has tested the AMPK hypothesis directly. The proposed mechanism is phosphorylation-level regulation of HMG-CoA reductase Gouni-Berthold 2002. In a human, that is testable with serum lathosterol and desmosterol as synthesis markers: if policosanol suppresses cholesterol synthesis, those fall, whether or not LDL-C does. Nobody has measured them on this compound.
Policosanol — its own safety story, not its category's
Its own safety story is that it does not have one, and the consequences of that are worth spelling out. Across the Cuban program and the independent replications, adverse events on policosanol were reported at placebo-like rates Castano 2001Berthold 2006. There is no upper limit set by toxicity, no organ signal, no withdrawal, no dependency. It is a purified plant wax and it behaves like one.
Which is precisely why it is still on the shelf. A supplement that did nothing and hurt people would have disappeared. A supplement that does nothing and is perfectly tolerated persists indefinitely, because nothing ever happens to falsify it in the customer's own experience. Being harmless is not the same as being safe to rely on.
The real harm is substitution, and it is quantifiable. Consider a reader with an ApoB of 130 mg/dL and a family history who chooses policosanol over a statin, or over the products with independent evidence. Twelve months on this compound is twelve months of unmodified atherogenic particle exposure, and cumulative particle-years is how coronary disease is actually built. That is a real cost, it is measurable, and no adverse event report will ever record it.
Interactions: none established, and that is not reassurance either. There is no documented cytochrome P450 or transporter interaction, which is unsurprising for a compound with no measured systemic exposure. The one caution worth stating is the blend problem — policosanol is often sold with red yeast rice, which contains monacolin K and is a statin, and every statin interaction applies to that ingredient.
And the boundary. If the reason you are here is a lipid number, the useful sentence is the one the card already gives: bergamot and plant sterols have independent support and this does not. This page exists to show the reader what a replication failure looks like from the inside, so that the next time a supplement arrives with twenty positive trials from one address, the pattern is recognizable.
Sources read for this page
- Berthold HK, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.. JAMA 2006 · PMID 16705107
- Kassis AN, et al. Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons.. American Journal of Clinical Nutrition 2006 · PMID 17093150
- Cubeddu LX, et al. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.. American Heart Journal 2006 · PMID 17070175
- Castano G, et al. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.. International Journal of Clinical Pharmacology Research 2001 · PMID 11708574
- Canetti M, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia.. International Journal of Clinical Pharmacology Research 1995 · PMID 8871266
- Crespo N, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.. International Journal of Clinical Pharmacology Research 1999 · PMID 10939029
- Gouni-Berthold I, et al. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent.. American Heart Journal 2002 · PMID 11835043
How you would know if it worked
Run this one expecting nothing, because that is what the independent evidence predicts. The striking lipid results came almost entirely from a single research group in Cuba working with Cuban sugarcane-derived material; randomized trials in Germany, the United States and elsewhere found no significant lipid effect at all. That makes a before-and-after lipid panel unusually worth running here, because it is one of the few places you can personally check a replication failure. Draw before the first capsule and again at 12 weeks. If your numbers do move, the interesting question is what else changed in those months — diet, weight, another supplement — since the compound itself has not moved lipids for any independent investigator who looked. Bergamot and plant sterols have the independent support this does not.
- Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) Retest: Every 3–6 months on androgens; annually otherwise.
- ApoB (Apolipoprotein B) Retest: Every 3–6 months on androgens or after any intervention; annually otherwise.
The cheapest panel carrying Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) and at least one other of these is Metabolic Health & Prediabetes, at $90 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Policosanol — safety & side effects
- Very well tolerated in trials — side-effect rates similar to placebo.
- The honest problem is that the impressive results came almost entirely from one research group in Cuba, and independent replications have largely failed. That is a reason to doubt the benefit rather than fear the harm.
- Mild antiplatelet activity. Not established as safe in pregnancy or breastfeeding — not because harm is documented, but because these are the two populations systematically excluded from the trials. Absence of data is not reassurance.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Policosanol in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Policosanol
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| ApoB (Apolipoprotein B) | Counts the particles that cause plaque — a normal LDL-C can hide risk |
| Lipoprotein(a) — Lp(a) | Genetic, largely unmodifiable, and worth knowing once in your life |
| hs-CRP (High-Sensitivity C-Reactive Protein) | The inflammatory half of cardiovascular risk |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | The standard baseline these are usually aimed at |
The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.
Check results you already have → · All 103 markers A–Z
Policosanol — frequently asked questions
What is Policosanol?
A useful case study in why replication matters. Early Cuban trials reported statin-like lipid effects; independent trials elsewhere found essentially nothing.
What is the suggested dose of Policosanol?
Not recommended on current evidence. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Policosanol dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Policosanol?
Coach Cam sources Policosanol from vetted, top-rated brands on iHerb — use the buy link on this page.
What Policosanol is used for
Policosanol appears under 1 goal in the goal router.
Related Cardiovascular supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.